Results 181 to 190 of about 512,677 (302)

Short and Long Non-Coding RNAs in Renal Cell Carcinoma. [PDF]

Noncoding RNA
Cecati M, Pozzi V, Schiavoni V, Barrasso G, Pompei V, Marzioni D, Bonci N, Fumarola S, Ballini A, Sartini D, Campagna R.   +10 more
europepmc   +1 more source

Long‐Term Outcomes of Reduced‐Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function

Arthritis &Rheumatology, EarlyView.
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean, Carrie Richardson, Anthony J. Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. [PDF]

Cell Death Dis
Liu B, Hou T, Liu X, Liu L, Ma Z, Zhang Y.   +5 more
europepmc   +1 more source

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng, Dandan Li, Yunyi Li, Chen Yun, Xinzhou Zhang, Wenyu Gong, Mengyun Xiao, Haitao Li, Zhipeng Zeng, Ruqi Tan, Yishen Yang, Shaodong Luan, Yong Dai, Lianghong Yin, Donge Tang   +14 more
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. [PDF]

Cancer Res
Koh J, Liao C, Ng MSW, Hong JH, Heng HL, Gui DY, Wang Z, Chua BY, Li Z, Sobota RM, Lee LS, Iqbal J, Lim KJ, Bezwada D, DeBerardinis RJ, Steger G, Ching J, Tan P, Teh BT, Zhang Q, Yao X.   +20 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Association of CMTM6 expression with clinicopathological characteristics and prognostic implications in renal cell carcinoma. [PDF]

Ther Adv Med Oncol
Tulchiner G, Fritz J, Rehder P, Bektic J, Zelger B, Jelisejevas L, Brunner A, Ladurner M.   +7 more
europepmc   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Clinicohistopathological characteristics of renal cell carcinoma in Jordan. [PDF]

Future Sci OA
Al-Zubi M, Haddad R, Badr A, Al Bibi H, Azzam S, Araydah M, Al Sharie A, Khattab K, Qasim H, Al Sharie S.   +9 more
europepmc   +1 more source